Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

NCT03850418 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Myeloid Malignancy

Interventions

DRUG: azacitidine

Sponsor

Henry Ford Health System